Immunomedics of Morris Plains, NJ, said last month that the EuropeanPatent Office has issued a decision maintaining its patent forusing antibodies for carcinoembryonic antigen (CEA) that are effectivefor targeting tumors with imaging and therapy agents.
Immunomedics of Morris Plains, NJ, said last month that the EuropeanPatent Office has issued a decision maintaining its patent forusing antibodies for carcinoembryonic antigen (CEA) that are effectivefor targeting tumors with imaging and therapy agents. The patenthad been challenged by Behringwerke AG of Germany, which did notappeal the patent office's decision denying its request, accordingto Immunomedics. The company's stock jumped 24% after the patentnews was announced.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.